← Back to Search

Corticosteroid

Cosyntropin for Stress and the Nervous System

N/A

Waitlist Available

Led By Gail Adler, MD, PhD

Research Sponsored by Brigham and Women's Hospital

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be between 18 and 65 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up baseline, 4-hours after infusion, 24-hours after infusion

Awards & highlights

Study Summary

This trial will test if a rise in ACTH (a stress hormone) causes delayed changes in the autonomic nervous system, which controls things like heart rate and blood pressure.

Eligible Conditions

Stress
Autonomic Nervous System
Baroreflexes

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ baseline, 4-hours after infusion, 24-hours after infusion

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~baseline, 4-hours after infusion, 24-hours after infusion

This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline, 4-hours after infusion, 24-hours after infusion for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Cardiovagal Baroreflex Sensitivity (Modified Oxford Technique)

Other outcome measures

Hippocampal Memory (Paired Associative Learning Task)

Pain (Quantitative Sensory Testing Using a Thermal Pain Testing Device)

Trial Design

2Treatment groups

Active Control

Placebo Group

Group I: CosyntropinActive Control1 Intervention

Subjects will receive cosyntropin infusion at 70 mcg/hr for two sessions of 2.5 hours each on day 2 of a three day admission to our research center.

Group II: Normal saline (Placebo)Placebo Group1 Intervention

Subjects will receive normal saline infusion for two sessions of 2.5 hours each on day 2 of a three day admission to our research center.

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Brigham and Women's HospitalLead Sponsor

1,609 Previous Clinical Trials

11,470,304 Total Patients Enrolled

Beth Israel Deaconess Medical CenterOTHER

836 Previous Clinical Trials

13,010,313 Total Patients Enrolled

Gail Adler, MD, PhDPrincipal InvestigatorBrigham and Women's Hospital

1 Previous Clinical Trials

20 Total Patients Enrolled

Media Library

Cosyntropin (Corticosteroid) Clinical Trial Eligibility Overview. Trial Name: NCT02339506 — N/A

Stress Research Study Groups: Cosyntropin, Normal saline (Placebo)

Stress Clinical Trial 2023: Cosyntropin Highlights & Side Effects. Trial Name: NCT02339506 — N/A

Cosyntropin (Corticosteroid) 2023 Treatment Timeline for Medical Study. Trial Name: NCT02339506 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is this research program open to individuals younger than 55 years old?

"This clinical trial requires that potential participants are between 18 and 55 years old in order to meet the criteria for enrolment."

Answered by AI

What medical purpose does Cosyntropin serve?

"Cosyntropin can be employed to manage ophthalmia, sympathetic disorders, panhypopituitarism and dermatomyositis (DM)."

Answered by AI

Do I fulfill the requirements to join this medical study?

"To qualify for this medical experiment, individuals must be between 18 and 55 years of age, experience some level of stress, as well as fulfil other physiological requirements. Approximately 23 people are needed to take part in the trial."

Answered by AI

Is there an enrollment period open for this research study?

"Unfortunately, recruitment for this trial has ceased. The study was initially posted on April 1st 2015 and the last update occured on July 18th 2022. Alternatives are available; 25 studies concerning stress, physiology and 5 trials regarding Cosyntropin are currently taking in participants."

Answered by AI

What is the current cap for enrollment in this experiment?

"Currently, this trial is not enrolling participants. Initially posted on April 1st 2015 and last modified July 18th 2022, no new applicants are being accepted at present. However, if you seek to join another investigation there are 25 distinct trials for stress-related issues initiated with physiological impact and 5 studies inviting volunteers for Cosyntropin testing."

Answered by AI

Recent research and studies

The Journal of Clinical Endocrinology & MetabolismJournal

HDL Cholesterol Efflux Capacity Is Impaired in Severe Short-term Hypothyroidism Despite Increased HDL Cholesterol

van der Boom, Trynke, Congzhuo Jia, Joop D Lefrandt, Margery A Connelly, Thera P Links, Uwe J F Tietge, and Robin P F Dullaart. 2020. “HDL Cholesterol Efflux Capacity Is Impaired in Severe Short-term Hypothyroidism Despite Increased HDL Cholesterol”. The Journal of Clinical Endocrinology & Metabolism. The Endocrine Society. doi:10.1210/clinem/dgaa411.

The Journal of Clinical Endocrinology & MetabolismJournal

ACTH Infusion Impairs Baroreflex Sensitivity—implications for Cardiovascular Hypoglycemia-associated Autonomic Failure

Leung, Janet H, Omar F Bayomy, Istvan Bonyhay, Johanna Celli, Jeffrey White, Roy Freeman, and Gail K Adler. 2020. “ACTH Infusion Impairs Baroreflex Sensitivity—implications for Cardiovascular Hypoglycemia-associated Autonomic Failure”. The Journal of Clinical Endocrinology & Metabolism. The Endocrine Society. doi:10.1210/clinem/dgaa221.

Endocrine ConnectionsJournal

Effect of Adrenocorticotropic Hormone Infusion on Circulating Sclerostin Levels

Zaheer, Sarah, Kayla Meyer, Rebecca Easly, Omar Bayomy, Janet Leung, Andrew W Koefoed, Mahyar Heydarpour, Roy Freeman, and Gail K Adler. 2021. “Effect of Adrenocorticotropic Hormone Infusion on Circulating Sclerostin Levels”. Endocrine Connections. Bioscientifica. doi:10.1530/ec-21-0263.

Endocrine ConnectionsJournal